| Project/Area Number |
23501291
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor immunology
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
WADA Haruka 北海道大学, 遺伝子病制御研究所, 講師 (70392181)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
SEINO Ken-ichiro 北海道大学, 遺伝子病制御研究所, 教授 (20312845)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | T細胞 / iPS細胞 / 再生医学的手法 / 分化誘導 / 細胞リプログラミング / 腫瘍免疫療法 / 腫瘍免疫 / リプログラミング / ＤＬＩ / DLI療法 |
|---|
| Research Abstract |
Outcomes of tumor treatment have been improved by development of multidisciplinary treatment. But, innovative tumor treatment strategy is eagerly anticipated. We proposed new strategy for tumor immunotherapy using cell reprogramming technology. In this study, we combined donor lymphocyte infusion (DLI) therapy and cell reprogramming technology. To do new DLI therapy, iPS cells are established from bone marrow donor cells. Usually, DLI treatment need donor lymphocyte on every treatment course, but this novel strategy make possible to do a continuous DLI treatment independent of lymphocyte donor. Then, it make possible to obtain T cell for DLI therapy every time you need. To test this concept, we established mice therapeutic model for leukemia relapse after bone marrow transplantation, and then we applied this new DLI treatment for this mice model. The mice survival were prolonged significantly depending on treatment frequency. It need more analysis to understand the response mechanisms.
|
